StockData
Aktis Oncology, Inc. logo

Aktis Oncology, Inc. (AKTS) stock

AKTSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026
$16.31+0.15 (+0.93%)

Close on Nov 17, 2026Market cap $907.15MP/E –Yield –

Aktis Oncology ebitda

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.

Quarterly ebitda

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026-$33.81M–
Q2 FY2026Jun 30, 2026-$28.02M–
Q1 FY2026Mar 31, 2026-$22.05M–
Q3 FY2025Sep 30, 2025-$17.61M–
Q2 FY2025Jun 30, 2025-$20.41M–
Q1 FY2025Mar 31, 2025-$17.66M–

More Aktis Oncology figures

See a number that looks wrong?